NASDAQ:FGEN - FibroGen Stock Price, Price Target & More

$46.55 -1.60 (-3.32 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$46.55
Today's Range$46.50 - $48.15
52-Week Range$25.35 - $63.00
Volume312,139 shs
Average Volume584,076 shs
Market Capitalization$4.04 billion
P/E Ratio-26.91
Dividend YieldN/A
Beta1.89

About FibroGen (NASDAQ:FGEN)

FibroGen logoFibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Receive FGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FGEN
CUSIPN/A
Phone415-978-1200

Debt

Debt-to-Equity Ratio0.17%
Current Ratio9.70%
Quick Ratio9.70%

Price-To-Earnings

Trailing P/E Ratio-26.91
Forward P/E Ratio-34.48
P/E GrowthN/A

Sales & Book Value

Annual Sales$125.67 million
Price / Sales30.62
Cash FlowN/A
Price / CashN/A
Book Value$7.09 per share
Price / Book6.57

Profitability

EPS (Most Recent Fiscal Year)($1.73)
Net Income$-126,200,000.00
Net Margins-100.43%
Return on Equity-32.08%
Return on Assets-18.17%

Miscellaneous

Employees423
Outstanding Shares82,670,000

How to Become a New Pot Stock Millionaire

FibroGen (NASDAQ:FGEN) Frequently Asked Questions

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen (NASDAQ:FGEN) posted its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.27) EPS for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.01. The biopharmaceutical company had revenue of $42.51 million for the quarter, compared to analysts' expectations of $45.37 million. FibroGen had a negative return on equity of 32.08% and a negative net margin of 100.43%. View FibroGen's Earnings History.

When is FibroGen's next earnings date?

FibroGen is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for FibroGen.

What price target have analysts set for FGEN?

7 brokerages have issued 1 year target prices for FibroGen's shares. Their predictions range from $31.00 to $88.00. On average, they expect FibroGen's share price to reach $66.6667 in the next twelve months. View Analyst Ratings for FibroGen.

What are Wall Street analysts saying about FibroGen stock?

Here are some recent quotes from research analysts about FibroGen stock:
  • 1. According to Zacks Investment Research, "FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California. " (3/5/2018)
  • 2. Mizuho analysts commented, "We believe Fibrogen is fairly priced. KeyPoints Earnings. For 3Q17, Fibrogen’s financials missed street estimates on reported revenue of $27.3 mil vs. consensus of $39.7 mil and missed on reported EPS of $(0.50) vs. consensus of $(0.37). License and milestone revenue recognized in the quarter appeared lower than expectations. R&D and SG&A expenses were approximately in-line with our prior projections. For 4Q17, Fibrogen expects to recognize a $15 mil milestone from AstraZeneca (AZN, not rated) related to roxadustat’s NDA filing in October 2017 in China. Quarterly earnings are usually not a driver for development stage companies like Fibrogen. In our opinion, news flow related to the pipeline development are more likely to be a catalyst. Progress for pamrevlumab in IPF. During the quarter Fibrogen reported positive topline results from their phase II trial for pamrevlumab in moderate- to-severe idiopathic pulmonary fibrosis (IPF) patients." (11/9/2017)

Who are some of FibroGen's key competitors?

Who are FibroGen's key executives?

FibroGen's management team includes the folowing people:
  • Mr. Thomas B. Neff, Founder, Chairman & CEO (Age 64)
  • Mr. Pat Cotroneo, VP of Fin. & CFO (Age 54)
  • Dr. K. Peony Yu M.D., Chief Medical Officer (Age 56)
  • Dr. Barry A. Berkowitz, Founder
  • Dr. Michael J. Martinelli Ph.D., VP of Technical Devel.

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Has FibroGen been receiving favorable news coverage?

News articles about FGEN stock have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. FibroGen earned a daily sentiment score of 0.17 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.42 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

How do I buy shares of FibroGen?

Shares of FGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $46.55.

How big of a company is FibroGen?

FibroGen has a market capitalization of $4.04 billion and generates $125.67 million in revenue each year. The biopharmaceutical company earns $-126,200,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. FibroGen employs 423 workers across the globe.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-978-1200 or via email at [email protected]


MarketBeat Community Rating for FibroGen (FGEN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  296
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe FGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

FibroGen (NASDAQ:FGEN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for FibroGen in the last 12 months. Their average twelve-month price target is $66.6667, suggesting that the stock has a possible upside of 43.22%. The high price target for FGEN is $88.00 and the low price target for FGEN is $31.00. There are currently 2 hold ratings, 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.862.862.862.88
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $66.6667$66.6667$65.6667$65.6667
Price Target Upside: 43.22% upside14.06% upside21.49% upside9.26% upside

FibroGen (NASDAQ:FGEN) Consensus Price Target History

Price Target History for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ:FGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018MizuhoReiterated RatingHold$61.00LowView Rating Details
2/28/2018Leerink SwannReiterated RatingOutperform$80.00 -> $88.00HighView Rating Details
9/14/2017Stifel NicolausReiterated RatingBuy$80.00LowView Rating Details
9/12/2017Jefferies GroupReiterated RatingBuy$75.00LowView Rating Details
8/9/2017William BlairReiterated RatingOutperformMediumView Rating Details
8/8/2017CitigroupBoost Price TargetTop Pick$48.00 -> $65.00HighView Rating Details
7/21/2017Goldman SachsDowngradeBuy -> Neutral$31.00MediumView Rating Details
1/18/2017Royal Bank of CanadaReiterated RatingBuyN/AView Rating Details
8/9/2016Credit Suisse GroupReiterated RatingBuy$37.00N/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

FibroGen (NASDAQ:FGEN) Earnings History and Estimates Chart

Earnings by Quarter for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ:FGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.44)
2019 EPS Consensus Estimate: $1.08
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.52)($0.48)($0.50)
Q2 20183($0.55)($0.51)($0.53)
Q3 20183($0.53)$0.00($0.34)
Q4 20183($0.75)$0.62($0.06)
Q1 20191$2.63$2.63$2.63
Q2 20191($0.79)($0.79)($0.79)
Q3 20191($0.77)($0.77)($0.77)
Q4 20191$0.01$0.01$0.01

FibroGen (NASDAQ FGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.55)N/AView Earnings Details
2/27/2018Q4 2017($0.28)($0.27)$45.37 million$42.51 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.37)($0.50)$41.34 million$27.27 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.47)($0.48)$34.80 million$29.00 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.63)($0.52)$26.02 million$26.89 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.53)($0.54)$19.29 million$31.91 millionViewListenView Earnings Details
11/8/2016Q3($0.63)($0.38)$24.30 million$30.10 millionViewListenView Earnings Details
8/8/2016Q2$0.36$0.35$80.58 million$89.28 millionViewListenView Earnings Details
5/9/2016Q116($0.56)($0.45)$16.89 million$28.28 millionViewListenView Earnings Details
2/29/2016Q4($0.54)($0.85)$40.44 million$24.44 millionViewListenView Earnings Details
11/12/2015Q3($0.6050)($0.74)$28.74 million$19.54 millionViewListenView Earnings Details
8/13/2015Q215$0.73$0.83$111.75 million$120.55 millionViewListenView Earnings Details
5/12/2015Q115($0.53)($0.78)$34.00 million$16.30 millionViewN/AView Earnings Details
3/26/2015Q414($0.90)($0.82)$16.49 million$16.11 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

FibroGen (NASDAQ:FGEN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

FibroGen (NASDAQ FGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.60%
Institutional Ownership Percentage: 61.39%
Insider Trading History for FibroGen (NASDAQ:FGEN)
Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

FibroGen (NASDAQ FGEN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018K Peony YuInsiderSell7,500$47.81$358,575.00156,233View SEC Filing  
4/9/2018Jorma RouttiDirectorSell6,000$46.59$279,540.00133,840View SEC Filing  
4/5/2018Thomas B NeffCEOSell39,636$45.59$1,807,005.242,950,813View SEC Filing  
3/21/2018Thomas B NeffCEOSell39,636$50.95$2,019,454.202,969,251View SEC Filing  
3/15/2018Pat CotroneoVPSell42,026$52.85$2,221,074.10168,334View SEC Filing  
3/15/2018Roberto Pedro RosenkranzDirectorSell1,000$52.34$52,340.0024,000View SEC Filing  
3/14/2018K Peony YuInsiderSell9,891$53.20$526,201.20128,333View SEC Filing  
3/13/2018Pat CotroneoCFOSell5,932$54.61$323,946.52168,334View SEC Filing  
3/12/2018Thomas F Kearns JrDirectorSell18,000$55.00$990,000.00135,064View SEC Filing  
3/9/2018Rory B RiggsDirectorSell22,905$55.75$1,276,953.75411,295View SEC Filing  
3/8/2018Pat CotroneoVPSell1,894$53.12$100,609.28176,160View SEC Filing  
3/8/2018Thomas B NeffCEOSell39,636$53.14$2,106,257.042,907,425View SEC Filing  
2/23/2018Thomas B NeffCEOSell39,636$56.66$2,245,775.762,955,614View SEC Filing  
2/16/2018Pat CotroneoVPSell49,500$55.96$2,770,020.00207,392View SEC Filing  
2/15/2018Kalevi KurkijarviDirectorSell6,000$55.69$334,140.0026,000View SEC Filing  
2/8/2018K Peony YuInsiderSell7,500$53.97$404,775.00144,986View SEC Filing  
1/30/2018Thomas B NeffCEOSell38,636$61.40$2,372,250.402,958,105View SEC Filing  
1/29/2018K Peony YuInsiderSell10,000$62.00$620,000.00152,086View SEC Filing  
1/26/2018Roberto Pedro RosenkranzDirectorSell6,000$60.00$360,000.0029,000View SEC Filing  
1/22/2018Pat CotroneoCFOSell25,000$48.72$1,218,000.00208,852View SEC Filing  
1/22/2018Roberto Pedro RosenkranzDirectorSell71$50.00$3,550.0036,929View SEC Filing  
1/18/2018Kalevi KurkijarviDirectorSell6,000$47.38$284,280.0028,000View SEC Filing  
1/18/2018Thomas B NeffCEOSell18,900$47.64$900,396.002,981,447View SEC Filing  
1/5/2018Thomas B NeffCEOSell38,636$47.61$1,839,459.963,029,887View SEC Filing  
12/29/2017Thomas B NeffCEOSell38,636$48.39$1,869,596.04View SEC Filing  
12/28/2017Thomas B NeffCEOSell18,900$48.29$912,681.003,071,705View SEC Filing  
12/21/2017Thomas B NeffCEOSell38,636$44.66$1,725,483.763,022,934View SEC Filing  
12/18/2017Kalevi KurkijarviDirectorSell2,000$42.80$85,600.0022,000View SEC Filing  
12/14/2017K Peony YuInsiderSell2,851$43.70$124,588.70162,086View SEC Filing  
12/14/2017Thomas B NeffCEOSell18,900$42.71$807,219.003,060,887View SEC Filing  
12/12/2017Kalevi KurkijarviDirectorSell12,000$44.45$533,400.0036,000View SEC Filing  
12/11/2017Pat CotroneoVPSell2,851$46.00$131,146.00183,852View SEC Filing  
12/4/2017Gerald LemaDirectorBuy3,500$46.70$163,450.003,500View SEC Filing  
12/1/2017Jorma RouttiDirectorSell12,000$47.25$567,000.00133,840View SEC Filing  
11/17/2017Kalevi KurkijarviDirectorSell2,000$46.65$93,300.0024,000View SEC Filing  
11/16/2017Thomas B NeffCEOSell18,900$46.60$880,740.003,109,555View SEC Filing  
11/15/2017Thomas F Kearns JrDirectorSell18,000$45.22$813,960.00156,564View SEC Filing  
11/6/2017K Peony YuInsiderSell7,500$55.37$415,275.00170,104View SEC Filing  
10/31/2017Thomas B NeffCEOSell38,636$56.13$2,168,638.683,144,573View SEC Filing  
10/17/2017Kalevi KurkijarviDirectorSell2,000$52.24$104,480.0026,000View SEC Filing  
10/17/2017Thomas B NeffCEOSell38,636$55.02$2,125,752.723,176,861View SEC Filing  
10/16/2017Thomas B NeffCEOSell18,900$54.83$1,036,287.003,176,861View SEC Filing  
10/4/2017K Peony YuInsiderSell15,000$60.00$900,000.00View SEC Filing  
10/3/2017Thomas B NeffCEOSell38,636$55.09$2,128,457.24View SEC Filing  
10/2/2017K Peony YuInsiderSell40,000$54.63$2,185,200.00View SEC Filing  
10/2/2017Thomas B NeffCEOSell18,900$54.45$1,029,105.003,217,455View SEC Filing  
9/20/2017Thomas B NeffCEOSell38,636$53.46$2,065,480.563,246,754View SEC Filing  
9/18/2017Kalevi KurkijarviDirectorSell4,000$46.65$186,600.0030,000View SEC Filing  
9/14/2017K Peony YuInsiderSell2,851$51.00$145,401.00185,546View SEC Filing  
9/14/2017Thomas B NeffCEOSell38,636$51.67$1,996,322.123,297,655View SEC Filing  
9/13/2017Rory B RiggsDirectorSell25,000$51.92$1,298,000.00435,200View SEC Filing  
9/13/2017Thomas B NeffCEOSell18,900$51.29$969,381.003,297,655View SEC Filing  
9/11/2017Pat CotroneoVPSell2,851$49.45$140,981.95157,405View SEC Filing  
9/1/2017Jorma RouttiDirectorSell12,000$47.36$568,320.00133,840View SEC Filing  
8/29/2017Thomas B NeffCEOSell38,636$43.73$1,689,552.283,330,780View SEC Filing  
8/28/2017Thomas B NeffCEOSell18,900$43.04$813,456.003,330,780View SEC Filing  
8/21/2017K Peony YuInsiderSell7,500$41.03$307,725.00191,507View SEC Filing  
8/17/2017Kalevi KurkijarviDirectorSell2,000$40.74$81,480.0030,000View SEC Filing  
8/8/2017K Peony YuInsiderSell37,500$50.58$1,896,750.00236,507View SEC Filing  
8/8/2017Pat CotroneoVPSell95,000$50.61$4,807,950.00173,366View SEC Filing  
8/2/2017Pat CotroneoVPSell28,346$33.97$962,913.62170,666View SEC Filing  
8/1/2017K Peony YuInsiderSell10,000$33.48$334,800.00226,507View SEC Filing  
7/25/2017Thomas B NeffCEOSell38,636$35.09$1,355,737.243,330,780View SEC Filing  
7/24/2017Thomas B NeffCEOSell18,900$35.06$662,634.003,330,780View SEC Filing  
7/17/2017Kalevi KurkijarviDirectorSell2,000$33.45$66,900.0032,000View SEC Filing  
7/10/2017K Peony YuInsiderSell5,000$32.98$164,900.00216,507View SEC Filing  
7/7/2017Thomas B NeffCEOSell38,636$33.38$1,289,669.683,330,780View SEC Filing  
7/6/2017Pat CotroneoVPSell4,000$34.00$136,000.00167,366View SEC Filing  
7/6/2017Thomas B NeffCEOSell18,900$33.53$633,717.003,330,780View SEC Filing  
6/22/2017Pat CotroneoVPSell3,000$32.00$96,000.00166,366View SEC Filing  
6/22/2017Thomas B NeffCEOSell38,636$31.52$1,217,806.723,330,780View SEC Filing  
6/19/2017Pat CotroneoVPSell5,500$30.00$165,000.00168,866View SEC Filing  
6/16/2017Thomas B NeffCEOSell38,636$29.40$1,135,898.403,330,780View SEC Filing  
6/15/2017Kalevi KurkijarviDirectorSell2,000$28.50$57,000.0034,000View SEC Filing  
6/14/2017K Peony YuInsiderSell3,721$28.95$107,722.95221,507View SEC Filing  
6/12/2017Pat CotroneoVPSell2,891$28.75$83,116.25163,366View SEC Filing  
6/12/2017Toshinari TamuraDirectorSell30,000$28.89$866,700.0060,000View SEC Filing  
6/6/2017Thomas F Kearns JrDirectorSell18,000$28.71$516,780.00156,564View SEC Filing  
5/31/2017Thomas B NeffCEOSell38,636$26.21$1,012,649.563,345,941View SEC Filing  
5/16/2017Kalevi KurkijarviDirectorSell2,000$27.40$54,800.0036,000View SEC Filing  
5/16/2017Thomas B NeffCEOSell38,636$27.70$1,070,217.203,345,941View SEC Filing  
5/15/2017Thomas B NeffCEOSell18,900$27.75$524,475.003,345,941View SEC Filing  
5/10/2017K Peony YuInsiderSell5,000$26.38$131,900.00227,346View SEC Filing  
4/25/2017K Peony YuInsiderSell5,000$28.00$140,000.00236,046View SEC Filing  
4/25/2017Pat CotroneoVPSell6,500$28.00$182,000.00164,405View SEC Filing  
4/25/2017Thomas B NeffCEOSell38,636$26.92$1,040,081.123,345,941View SEC Filing  
4/24/2017Thomas B NeffCEOSell18,900$26.35$498,015.003,345,941View SEC Filing  
4/17/2017Kalevi KurkijarviDirectorSell2,000$25.25$50,500.0038,000View SEC Filing  
4/13/2017Thomas B NeffCEOSell38,636$24.79$957,786.443,345,941View SEC Filing  
4/4/2017Thomas B NeffCEOSell38,636$23.92$924,173.123,345,941View SEC Filing  
3/21/2017Thomas B NeffCEOSell38,636$24.34$940,400.243,345,941View SEC Filing  
3/20/2017Thomas B NeffCEOSell18,900$24.88$470,232.003,345,941View SEC Filing  
3/15/2017Thomas B NeffCEOSell38,636$25.07$968,604.523,353,983View SEC Filing  
2/16/2017Kalevi KurkijarviDirectorSell2,000$24.45$48,900.0040,000View SEC Filing  
2/14/2017Thomas B NeffCEOSell38,636$23.94$924,945.843,274,061View SEC Filing  
2/13/2017Thomas B NeffCEOSell18,900$23.97$453,033.003,274,061View SEC Filing  
2/9/2017Thomas B NeffCEOSell37,798$23.46$886,741.083,278,868View SEC Filing  
1/27/2017Thomas B NeffCEOSell37,798$23.29$880,315.423,288,484View SEC Filing  
1/19/2017Kalevi KurkijarviDirectorSell2,000$24.90$49,800.0042,000View SEC Filing  
1/12/2017Thomas B NeffCEOSell37,798$23.85$901,482.303,298,100View SEC Filing  
1/11/2017Pat CotroneoVPSell6,500$24.00$156,000.00138,748View SEC Filing  
1/10/2017K Peony YuInsiderSell5,000$23.56$117,800.00202,448View SEC Filing  
12/28/2016Thomas B NeffCEOSell37,798$20.74$783,930.523,307,718View SEC Filing  
12/16/2016Rory B RiggsDirectorSell20,000$20.87$417,400.00460,200View SEC Filing  
12/13/2016Thomas B NeffCEOSell37,798$21.24$802,829.523,317,334View SEC Filing  
12/12/2016Pat CotroneoVPSell2,344$22.05$51,685.20132,248View SEC Filing  
12/12/2016Thomas B NeffCEOSell18,899$21.48$405,950.523,317,334View SEC Filing  
11/29/2016Thomas B NeffCEOSell37,798$22.80$861,794.403,331,639View SEC Filing  
11/28/2016Thomas B NeffCEOSell18,899$22.74$429,763.263,331,639View SEC Filing  
11/18/2016Thomas F Kearns JrDirectorSell18,000$22.40$403,200.00165,564View SEC Filing  
11/17/2016Thomas B NeffCEOSell37,798$22.29$842,517.423,341,255View SEC Filing  
11/1/2016Thomas B NeffCEOSell37,798$16.76$633,494.483,350,871View SEC Filing  
10/19/2016Thomas B NeffCEOSell37,798$17.75$670,914.503,360,487View SEC Filing  
10/18/2016Thomas B NeffCEOSell18,899$17.94$339,048.063,360,487View SEC Filing  
10/4/2016Thomas B NeffCEOSell18,899$20.67$390,642.333,370,103View SEC Filing  
10/3/2016Thomas B NeffCEOSell18,899$20.55$388,374.453,370,103View SEC Filing  
9/21/2016Thomas B NeffCEOSell37,798$21.66$818,704.683,379,719View SEC Filing  
9/14/2016K Peony YuInsiderSell2,345$18.66$43,757.70206,502View SEC Filing  
9/12/2016Pat CotroneoVPSell2,345$18.22$42,725.90134,359View SEC Filing  
9/9/2016Thomas B NeffCEOSell37,798$18.99$717,784.023,389,335View SEC Filing  
8/26/2016Thomas B NeffCEOSell37,798$17.80$672,804.403,403,639View SEC Filing  
7/27/2016Thomas B NeffCEOSell37,798$18.38$694,727.243,413,255View SEC Filing  
7/13/2016Thomas B NeffCEOSell27,000$17.50$472,500.003,412,664View SEC Filing  
6/29/2016Thomas B NeffCEOSell27,000$16.02$432,540.003,439,764View SEC Filing  
6/15/2016Pat CotroneoCFOSell1,796$16.49$29,616.04138,114View SEC Filing  
6/15/2016Thomas B NeffCEOSell27,000$16.48$444,960.003,466,664View SEC Filing  
6/10/2016K Peony YuInsiderSell2,344$17.96$42,098.24210,257View SEC Filing  
6/3/2016Thomas B NeffCEOSell27,000$18.99$512,730.003,507,164View SEC Filing  
5/20/2016Thomas B NeffCEOSell27,000$17.68$477,360.003,526,053View SEC Filing  
5/16/2016Pat CotroneoCFOSell6,107$17.60$107,483.20141,868View SEC Filing  
5/3/2016Thomas B NeffCEOSell27,000$17.78$480,060.003,552,353View SEC Filing  
4/20/2016Thomas B NeffCEOSell27,000$19.98$539,460.003,579,353View SEC Filing  
4/19/2016Thomas B NeffCEOSell13,500$20.21$272,835.003,579,353View SEC Filing  
4/5/2016Thomas B NeffCEOSell27,000$21.11$569,970.003,606,353View SEC Filing  
4/1/2016Frank H Md ValoneInsiderSell10,750$21.11$226,932.50115,434View SEC Filing  
3/22/2016Thomas B NeffCEOSell27,000$18.74$505,980.003,633,453View SEC Filing  
3/8/2016Thomas B NeffCEOSell27,000$19.62$529,740.003,667,175View SEC Filing  
3/1/2016Frank H Md ValoneInsiderSell10,750$16.84$181,030.00115,133View SEC Filing  
2/23/2016Thomas B NeffCEOSell27,000$19.11$515,970.003,596,207View SEC Filing  
2/22/2016Thomas B NeffCEOSell13,500$19.81$267,435.003,596,207View SEC Filing  
2/16/2016Frank H. Md ValoneinsiderSell10,750$18.41$197,907.5096,840View SEC Filing  
2/10/2016Thomas B. NeffCEOSell27,000$15.31$413,370.003,609,407View SEC Filing  
1/29/2016Thomas B. NeffCEOSell27,000$19.41$524,070.003,636,407View SEC Filing  
1/21/2016Thomas F Kearns JrDirectorSell1,572$22.08$34,709.76160,564View SEC Filing  
1/14/2016Thomas B. NeffCEOSell27,000$23.69$639,630.003,663,407View SEC Filing  
12/24/2015Thomas F. Kearns, Jr.DirectorSell7,800$30.88$240,864.00162,136View SEC Filing  
12/23/2015Thomas B. NeffCEOSell27,000$30.10$812,700.003,690,407View SEC Filing  
12/11/2015Thomas B. NeffCEOSell27,000$29.59$798,930.003,717,407View SEC Filing  
12/10/2015K Peony YuVPSell1,093$28.96$31,653.28176,595View SEC Filing  
12/8/2015Miguel MaderoDirectorSell40,386$30.49$1,231,369.1455,614View SEC Filing  
11/30/2015K Peony YuVPSell5,000$30.00$150,000.00178,345View SEC Filing  
11/25/2015Pat CotroneoCFOSell5,000$30.00$150,000.00107,775View SEC Filing  
11/24/2015Thomas B. NeffCEOSell13,500$28.98$391,230.003,746,689View SEC Filing  
11/24/2015Thomas F. Kearns, Jr.DirectorSell3,900$29.00$113,100.00169,936View SEC Filing  
11/23/2015Thomas B. NeffCEOSell13,500$27.99$377,865.003,746,689View SEC Filing  
11/23/2015Thomas F. Kearns, Jr.DirectorSell3,900$28.02$109,278.00169,936View SEC Filing  
11/17/2015K Peony YuVPSell5,000$28.00$140,000.00183,345View SEC Filing  
11/10/2015K Peony YuVPSell5,000$25.62$128,100.00187,904View SEC Filing  
11/9/2015K Peony YuVPSell2,500$25.00$62,500.00187,904View SEC Filing  
11/2/2015Frank H. Md ValoneinsiderSell10,000$23.18$231,800.0084,044View SEC Filing  
10/30/2015Thomas B. NeffCEOSell27,000$24.06$649,620.003,773,689View SEC Filing  
10/21/2015Thomas F. Kearns, Jr.DirectorSell7,800$23.83$185,874.00177,736View SEC Filing  
10/19/2015Frank H. Md ValoneinsiderSell10,000$23.00$230,000.0084,044View SEC Filing  
10/19/2015K Peony YuVPSell5,000$24.00$120,000.00192,904View SEC Filing  
10/16/2015K Peony YuVPSell5,000$21.46$107,300.00197,904View SEC Filing  
10/16/2015Thomas B. NeffCEOSell27,000$21.86$590,220.003,800,689View SEC Filing  
10/2/2015Thomas B. NeffCEOSell27,000$21.59$582,930.003,827,689View SEC Filing  
10/1/2015Frank H. Md ValoneinsiderSell10,000$21.38$213,800.0084,044View SEC Filing  
9/18/2015Thomas B. NeffCEOSell27,000$29.10$785,700.003,854,689View SEC Filing  
9/15/2015Pat CotroneoCFOSell1,093$27.95$30,549.35107,498View SEC Filing  
9/14/2015Rory B. RiggsDirectorSell50,000$27.61$1,380,500.00480,200View SEC Filing  
9/11/2015Miguel MaderoDirectorSell20,600$27.66$569,796.0012,000View SEC Filing  
9/10/2015K Peony YuVPSell1,093$27.84$30,429.12202,904View SEC Filing  
9/10/2015Pat CotroneoCFOSell7,500$27.33$204,975.00107,251View SEC Filing  
9/4/2015Thomas B. NeffCEOSell13,500$22.88$308,880.003,862,751View SEC Filing  
9/3/2015Thomas B. NeffCEOSell13,500$22.92$309,420.003,866,782View SEC Filing  
9/1/2015Frank H. Md ValoneinsiderSell10,000$23.58$235,800.0084,044View SEC Filing  
7/23/2015Thomas B NeffCEOSell27,000$24.71$667,170.00View SEC Filing  
7/20/2015Frank H Md ValoneInsiderSell1,000$23.70$23,700.00View SEC Filing  
7/20/2015Pat CotroneoCFOSell7,881$23.47$184,967.07View SEC Filing  
7/9/2015Thomas B NeffCEOSell27,000$22.11$596,970.00View SEC Filing  
7/6/2015K Peony YuVPSell5,381$22.69$122,094.89View SEC Filing  
6/25/2015Thomas B NeffCEOSell27,000$23.57$636,390.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

FibroGen (NASDAQ FGEN) News Headlines

Source:
DateHeadline
Form 4 FIBROGEN INC For: Apr 16 Filed by: Yu K PeonyForm 4 FIBROGEN INC For: Apr 16 Filed by: Yu K Peony
www.streetinsider.com - April 19 at 9:10 AM
Insider Selling: FibroGen (FGEN) Insider Sells 7,500 Shares of StockInsider Selling: FibroGen (FGEN) Insider Sells 7,500 Shares of Stock
www.americanbankingnews.com - April 18 at 7:28 PM
FibroGen (FGEN) Stock Rating Lowered by BidaskClubFibroGen (FGEN) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 10:53 PM
FibroGen (FGEN) Expected to Announce Quarterly Sales of $28.23 MillionFibroGen (FGEN) Expected to Announce Quarterly Sales of $28.23 Million
www.americanbankingnews.com - April 14 at 2:02 AM
 Brokerages Anticipate FibroGen (FGEN) Will Post Earnings of -$0.51 Per Share Brokerages Anticipate FibroGen (FGEN) Will Post Earnings of -$0.51 Per Share
www.americanbankingnews.com - April 12 at 9:16 PM
FibroGen (FGEN) Rating Reiterated by Jefferies GroupFibroGen (FGEN) Rating Reiterated by Jefferies Group
www.americanbankingnews.com - April 12 at 9:00 PM
Stifel Nicolaus Raises FibroGen (FGEN) Price Target to $80.00Stifel Nicolaus Raises FibroGen (FGEN) Price Target to $80.00
www.americanbankingnews.com - April 12 at 9:00 PM
FibroGen (FGEN) Director Sells $279,540.00 in StockFibroGen (FGEN) Director Sells $279,540.00 in Stock
www.americanbankingnews.com - April 11 at 10:37 PM
William Blair Reiterates Outperform Rating for FibroGen (FGEN)William Blair Reiterates Outperform Rating for FibroGen (FGEN)
www.americanbankingnews.com - April 11 at 6:13 PM
A Look at FibroGen’s Cash Flow Generating CapacityA Look at FibroGen’s Cash Flow Generating Capacity
finance.yahoo.com - April 9 at 9:25 AM
Thomas B. Neff Sells 39,636 Shares of FibroGen (FGEN) StockThomas B. Neff Sells 39,636 Shares of FibroGen (FGEN) Stock
www.americanbankingnews.com - April 6 at 10:27 PM
Understanding FibroGen’s Research PipelineUnderstanding FibroGen’s Research Pipeline
finance.yahoo.com - April 6 at 9:35 AM
FibroGens (FGEN) "Hold" Rating Reaffirmed at MizuhoFibroGen's (FGEN) "Hold" Rating Reaffirmed at Mizuho
www.americanbankingnews.com - March 31 at 8:16 PM
FibroGen (FGEN) Given Hold Rating at MizuhoFibroGen (FGEN) Given Hold Rating at Mizuho
www.americanbankingnews.com - March 29 at 5:16 PM
FibroGen (FGEN) Given Consensus Recommendation of "Hold" by AnalystsFibroGen (FGEN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 28 at 1:38 AM
$28.23 Million in Sales Expected for FibroGen (FGEN) This Quarter$28.23 Million in Sales Expected for FibroGen (FGEN) This Quarter
www.americanbankingnews.com - March 28 at 1:02 AM
 Brokerages Expect FibroGen (FGEN) Will Post Earnings of -$0.51 Per Share Brokerages Expect FibroGen (FGEN) Will Post Earnings of -$0.51 Per Share
www.americanbankingnews.com - March 26 at 11:08 PM
Technical Perspectives on Biotech Stocks -- Eyegate Pharma, Fate Therapeutics, FibroGen, and Genocea BiosciencesTechnical Perspectives on Biotech Stocks -- Eyegate Pharma, Fate Therapeutics, FibroGen, and Genocea Biosciences
www.prnewswire.com - March 26 at 7:42 AM
FibroGen (FGEN) Upgraded by ValuEngine to "Hold"FibroGen (FGEN) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - March 25 at 6:25 PM
FibroGen (FGEN) Lifted to C- at TheStreetFibroGen (FGEN) Lifted to C- at TheStreet
www.americanbankingnews.com - March 24 at 3:53 PM
FibroGen (FGEN) CEO Thomas B. Neff Sells 39,636 SharesFibroGen (FGEN) CEO Thomas B. Neff Sells 39,636 Shares
www.americanbankingnews.com - March 22 at 10:22 PM
FibroGen (FGEN) Receives Patent for Enhanced Erythropoiesis and Iron Metabolism - StreetInsider.comFibroGen (FGEN) Receives Patent for Enhanced Erythropoiesis and Iron Metabolism - StreetInsider.com
www.streetinsider.com - March 22 at 4:44 PM
FibroGen Inc (FGEN) Director Roberto Pedro Rosenkranz Sells 1,000 SharesFibroGen Inc (FGEN) Director Roberto Pedro Rosenkranz Sells 1,000 Shares
www.americanbankingnews.com - March 16 at 8:32 PM
FibroGen Inc (FGEN) Insider Sells $526,201.20 in StockFibroGen Inc (FGEN) Insider Sells $526,201.20 in Stock
www.americanbankingnews.com - March 16 at 7:52 PM
Insider Selling: FibroGen Inc (FGEN) CFO Sells 5,932 Shares of StockInsider Selling: FibroGen Inc (FGEN) CFO Sells 5,932 Shares of Stock
www.americanbankingnews.com - March 16 at 4:08 AM
FibroGen Inc (FGEN) VP Sells $2,221,074.10 in StockFibroGen Inc (FGEN) VP Sells $2,221,074.10 in Stock
www.americanbankingnews.com - March 15 at 10:10 PM
FibroGen Inc (FGEN) Director Thomas F. Kearns, Jr. Sells 18,000 SharesFibroGen Inc (FGEN) Director Thomas F. Kearns, Jr. Sells 18,000 Shares
www.americanbankingnews.com - March 13 at 10:11 PM
 Brokerages Anticipate FibroGen Inc (FGEN) Will Post Quarterly Sales of $28.23 Million Brokerages Anticipate FibroGen Inc (FGEN) Will Post Quarterly Sales of $28.23 Million
www.americanbankingnews.com - March 11 at 5:58 AM
FibroGen Inc (FGEN) Director Sells $1,276,953.75 in StockFibroGen Inc (FGEN) Director Sells $1,276,953.75 in Stock
www.americanbankingnews.com - March 9 at 9:15 PM
 Brokerages Expect FibroGen Inc (FGEN) Will Post Earnings of -$0.51 Per Share Brokerages Expect FibroGen Inc (FGEN) Will Post Earnings of -$0.51 Per Share
www.americanbankingnews.com - March 9 at 4:33 PM
FibroGen Inc (FGEN) VP Sells $100,609.28 in StockFibroGen Inc (FGEN) VP Sells $100,609.28 in Stock
www.americanbankingnews.com - March 8 at 9:50 PM
Insider Selling: FibroGen Inc (FGEN) CEO Sells 39,636 Shares of StockInsider Selling: FibroGen Inc (FGEN) CEO Sells 39,636 Shares of Stock
www.americanbankingnews.com - March 8 at 9:15 PM
Landscape Capital Management L.L.C. Purchases Shares of 26,642 FibroGen Inc (FGEN)Landscape Capital Management L.L.C. Purchases Shares of 26,642 FibroGen Inc (FGEN)
www.americanbankingnews.com - March 6 at 1:05 PM
FibroGen (FGEN) Rating Lowered to Sell at Zacks Investment ResearchFibroGen (FGEN) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 5 at 11:14 PM
FibroGen Inc Expected to Post Q1 2018 Earnings of ($0.50) Per Share (FGEN)FibroGen Inc Expected to Post Q1 2018 Earnings of ($0.50) Per Share (FGEN)
www.americanbankingnews.com - March 5 at 2:24 AM
ValuEngine Lowers FibroGen (FGEN) to SellValuEngine Lowers FibroGen (FGEN) to Sell
www.americanbankingnews.com - March 4 at 6:42 PM
Teacher Retirement System of Texas Boosts Position in FibroGen Inc (FGEN)Teacher Retirement System of Texas Boosts Position in FibroGen Inc (FGEN)
www.americanbankingnews.com - March 4 at 7:06 AM
FibroGen Inc (FGEN) Holdings Increased by State of Wisconsin Investment BoardFibroGen Inc (FGEN) Holdings Increased by State of Wisconsin Investment Board
www.americanbankingnews.com - March 3 at 8:44 AM
FibroGen Inc (FGEN) Given Average Rating of "Buy" by AnalystsFibroGen Inc (FGEN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - March 3 at 1:26 AM
Jefferies Group Analysts Decrease Earnings Estimates for FibroGen Inc (FGEN)Jefferies Group Analysts Decrease Earnings Estimates for FibroGen Inc (FGEN)
www.americanbankingnews.com - March 2 at 2:30 PM
Equities Analysts Issue Forecasts for FibroGen Incs Q3 2018 Earnings (FGEN)Equities Analysts Issue Forecasts for FibroGen Inc's Q3 2018 Earnings (FGEN)
www.americanbankingnews.com - March 2 at 11:33 AM
FibroGen Inc (FGEN) to Post Q1 2018 Earnings of ($0.52) Per Share, William Blair ForecastsFibroGen Inc (FGEN) to Post Q1 2018 Earnings of ($0.52) Per Share, William Blair Forecasts
www.americanbankingnews.com - March 2 at 9:30 AM
BRIEF-FibroGen Gets FDA Fast Track Designation For Its Pancreatic Cancer TreatmentBRIEF-FibroGen Gets FDA Fast Track Designation For Its Pancreatic Cancer Treatment
www.reuters.com - March 1 at 5:01 PM
UPDATE - FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic CancerUPDATE - FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer
finance.yahoo.com - March 1 at 5:01 PM
William Blair Comments on FibroGen Incs Q1 2019 Earnings (FGEN)William Blair Comments on FibroGen Inc's Q1 2019 Earnings (FGEN)
www.americanbankingnews.com - March 1 at 2:08 PM
BRIEF-Fibrogen Granted Fast Track Designation By U.S. FDA For Pamrevlumab Treatment Of PatientsBRIEF-Fibrogen Granted Fast Track Designation By U.S. FDA For Pamrevlumab Treatment Of Patients
www.reuters.com - March 1 at 8:58 AM
Fibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic CancerFibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic Cancer
finance.yahoo.com - March 1 at 8:58 AM
FibroGen (FGEN) Given "Outperform" Rating at Leerink SwannFibroGen (FGEN) Given "Outperform" Rating at Leerink Swann
www.americanbankingnews.com - March 1 at 12:30 AM
Swiss National Bank Increases Stake in FibroGen Inc (FGEN)Swiss National Bank Increases Stake in FibroGen Inc (FGEN)
www.americanbankingnews.com - February 28 at 5:14 PM
FibroGen Q4 Earnings OutlookFibroGen Q4 Earnings Outlook
finance.yahoo.com - February 27 at 5:14 PM

SEC Filings

FibroGen (NASDAQ:FGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

FibroGen (NASDAQ:FGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

FibroGen (NASDAQ FGEN) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.